Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
0.3168
-0.0273 (-7.93%)
Mar 27, 2026, 1:52 PM EDT - Market open
Sangamo Therapeutics Stock Forecast
SGMO's stock price has decreased by -61.33% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 3 analysts that cover Sangamo Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $7.00, which forecasts a 2,109.60% increase in the stock price over the next year. The lowest target is $1.00 and the highest is $10.
Price Target: $7.00 (+2,109.60%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 10, 2026.
Analyst Ratings
The average analyst rating for Sangamo Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 2 | 2 |
| Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 3 | 3 | 3 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +3,056.57% | Feb 10, 2026 |
| Barclays | Barclays | Buy → Hold Downgrades $5 → $1 | Buy → Hold | Downgrades | $5 → $1 | +215.66% | Nov 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +3,056.57% | Sep 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +3,056.57% | Jun 24, 2025 |
| Barclays | Barclays | Buy Maintains $9 → $5 | Buy | Maintains | $9 → $5 | +1,478.28% | May 14, 2025 |
Financial Forecast
Revenue This Year
60.57M
from 57.80M
Increased by 4.79%
Revenue Next Year
49.23M
from 60.57M
Decreased by -18.73%
EPS This Year
-0.34
from -0.49
EPS Next Year
-0.28
from -0.34
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 131.6M | 119.7M | ||||
| Avg | 60.6M | 49.2M | ||||
| Low | 34.0M | 8.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 127.6% | 97.6% | ||||
| Avg | 4.8% | -18.7% | ||||
| Low | -41.2% | -86.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.13 | -0.11 | ||||
| Avg | -0.34 | -0.28 | ||||
| Low | -0.42 | -0.41 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.